GlassScriptPhysician profile
Marissa A Maclin
NPI 1619296902
$1,151.80
in general payments reported to CMS, 2019-2025
14 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2024: $338 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $235.47 | 2021-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $217.71 | 2021-2025 | |
| Nevro Corp. | $145.72 | 2021 | |
| Allergan, INC. | $90.13 | 2021 | |
| Abbott Laboratories | $70.89 | 2025 | Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.43 | 2024-2025 | Relistor |
| Lundbeck LLC | $63.60 | 2024-2025 | Vyepti |
| Biotronik Nro, INC. | $60.49 | 2025 | Prospera |
| Valinor Pharma, LLC | $57.82 | 2024 | Movantik |
| Boston Scientific Corporation | $45.95 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Biodelivery Sciences International, INC. | $34.47 | 2021 | |
| Grt US Holding, INC. | $23.55 | 2021 | |
| Merz Pharmaceuticals, LLC | $21.48 | 2024 | Inbrija, Xeomin |
| Curonix LLC | $15.09 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Maclin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.